[go: up one dir, main page]

EA201200102A1 - Соединения, применимые в качестве лекарственных средств - Google Patents

Соединения, применимые в качестве лекарственных средств

Info

Publication number
EA201200102A1
EA201200102A1 EA201200102A EA201200102A EA201200102A1 EA 201200102 A1 EA201200102 A1 EA 201200102A1 EA 201200102 A EA201200102 A EA 201200102A EA 201200102 A EA201200102 A EA 201200102A EA 201200102 A1 EA201200102 A1 EA 201200102A1
Authority
EA
Eurasian Patent Office
Prior art keywords
medicine
compounds applicable
compounds
applicable
useful
Prior art date
Application number
EA201200102A
Other languages
English (en)
Other versions
EA026674B1 (ru
Inventor
Якоб Вестман
Аллан Халлет
Ян Вагберг
Original Assignee
Балтик Био Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Балтик Био Аб filed Critical Балтик Био Аб
Publication of EA201200102A1 publication Critical patent/EA201200102A1/ru
Publication of EA026674B1 publication Critical patent/EA026674B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Согласно настоящему изобретению предоставляется соединение формулы Iгде X, W, A-Аи D являются такими, как указано в раскрытии изобретения, где данные соединения являются пригодными для лечения рака.
EA201200102A 2009-07-08 2010-07-08 Соединения, применимые в качестве лекарственных средств EA026674B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21373509P 2009-07-08 2009-07-08
PCT/GB2010/001315 WO2011004162A2 (en) 2009-07-08 2010-07-08 Compounds useful as medicaments

Publications (2)

Publication Number Publication Date
EA201200102A1 true EA201200102A1 (ru) 2012-08-30
EA026674B1 EA026674B1 (ru) 2017-05-31

Family

ID=43086401

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200102A EA026674B1 (ru) 2009-07-08 2010-07-08 Соединения, применимые в качестве лекарственных средств

Country Status (24)

Country Link
US (2) US9162994B2 (ru)
EP (1) EP2451794B1 (ru)
JP (1) JP5982281B2 (ru)
KR (1) KR101765957B1 (ru)
CN (1) CN102596923B (ru)
AU (1) AU2010270030B2 (ru)
BR (1) BR112012000370B1 (ru)
CA (1) CA2767291C (ru)
DK (1) DK2451794T3 (ru)
EA (1) EA026674B1 (ru)
ES (1) ES2567753T3 (ru)
HR (1) HRP20160353T1 (ru)
HU (1) HUE027263T2 (ru)
IL (1) IL216723A (ru)
ME (1) ME02443B (ru)
MX (1) MX337516B (ru)
NZ (1) NZ597075A (ru)
PL (1) PL2451794T3 (ru)
RS (1) RS54718B1 (ru)
SG (1) SG177558A1 (ru)
SI (1) SI2451794T1 (ru)
SM (1) SMT201600225B (ru)
WO (1) WO2011004162A2 (ru)
ZA (1) ZA201108901B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931145B1 (ko) * 2008-07-04 2009-12-10 현대자동차주식회사 조정식 킥 다운 스위치의 조작기구
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
JP6751203B2 (ja) 2016-06-07 2020-09-02 ジャコバイオ ファーマスーティカルズ カンパニー リミテッドJacobio Pharmaceuticals Co., Ltd. Shp2阻害剤として有用な新規複素環式誘導体
LT3571193T (lt) 2017-01-23 2022-02-10 Cadent Therapeutics, Inc. Kalio kanalo moduliatoriai
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
KR20210080446A (ko) 2018-10-22 2021-06-30 카덴트 테라퓨틱스, 인크. 칼륨 채널 조절제의 결정 형태
US20220023269A1 (en) * 2018-11-05 2022-01-27 Balticgruppen Bio Ab Methods Of Treating Diabetes In Severe Insulin-Resistant Diabetic Subjects
CN109879808B (zh) * 2019-03-05 2020-10-16 北京工业大学 一种含五元唑类杂环基查尔酮类衍生物及制备方法和医药用途
GB201910092D0 (en) 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
GB201910093D0 (en) 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB202015585D0 (en) * 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
GB202112529D0 (en) 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
WO2025017193A1 (en) 2023-07-20 2025-01-23 Betagenon Ab Methods of treating cardiomyopathy induced by metabolic inflexibility
WO2025017194A1 (en) 2023-07-20 2025-01-23 Betagenon Ab Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler
WO2025027205A1 (en) 2023-08-03 2025-02-06 Betagenon Ab Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide
WO2025252672A1 (en) 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093624A (en) 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
ATE366238T1 (de) 2000-05-11 2007-07-15 Consejo Superior Investigacion Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
WO2006045581A1 (en) 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
US20090136472A1 (en) 2005-07-21 2009-05-28 Jacob Westman Use of thiazole derivatives and analogues in disorders caused by free fatty acids
WO2008090356A1 (en) 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity

Also Published As

Publication number Publication date
NZ597075A (en) 2013-03-28
JP5982281B2 (ja) 2016-08-31
JP2012532854A (ja) 2012-12-20
EA026674B1 (ru) 2017-05-31
RS54718B1 (sr) 2016-08-31
ME02443B (me) 2016-09-20
KR101765957B1 (ko) 2017-08-07
BR112012000370B1 (pt) 2019-04-16
KR20120054568A (ko) 2012-05-30
MX337516B (es) 2016-03-09
SMT201600225B (it) 2016-08-31
US20120183537A1 (en) 2012-07-19
ES2567753T3 (es) 2016-04-26
CN102596923A (zh) 2012-07-18
EP2451794B1 (en) 2016-01-27
WO2011004162A3 (en) 2011-03-03
IL216723A0 (en) 2012-03-01
SI2451794T1 (sl) 2016-05-31
SG177558A1 (en) 2012-02-28
DK2451794T3 (en) 2016-03-14
US9675596B2 (en) 2017-06-13
HRP20160353T1 (hr) 2016-05-06
AU2010270030A1 (en) 2012-01-12
MX2012000441A (es) 2012-04-19
HK1170485A1 (zh) 2013-03-01
US9162994B2 (en) 2015-10-20
ZA201108901B (en) 2017-08-30
EP2451794A2 (en) 2012-05-16
CN102596923B (zh) 2015-04-29
AU2010270030B2 (en) 2015-12-24
CA2767291A1 (en) 2011-01-13
IL216723A (en) 2017-09-28
CA2767291C (en) 2020-01-28
PL2451794T3 (pl) 2016-07-29
BR112012000370A2 (pt) 2016-11-22
WO2011004162A2 (en) 2011-01-13
US20160128993A1 (en) 2016-05-12
HUE027263T2 (en) 2016-10-28

Similar Documents

Publication Publication Date Title
EA201200102A1 (ru) Соединения, применимые в качестве лекарственных средств
EA201290800A1 (ru) Гетероциклическое соединение
UA110338C2 (xx) Хімічні сполуки
EA201291317A1 (ru) Тетрагидропиридопиримидиновые производные
MY159850A (en) Tetracyclic compounds
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
NZ597517A (en) 5-fluoropyrimidinone derivatives
MX2011011094A (es) Derivados de prolina como inhibidores de catepsina.
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
WO2011019634A3 (en) Aryl substituted sulfonamide compounds and their use as anticancer agents
MD20140047A2 (ru) Ингибиторы протеинкиназы
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
EA201290632A1 (ru) Производные бетулина
MX2014003283A (es) Composiciones farmaceuticas.
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
UA107455C2 (ru) Производные индола как противораковые агенты
EA200900946A1 (ru) Новый способ синтеза агомелатина
EA201101675A1 (ru) Спироэпоксиды как промежуточные продукты синтеза
EA201070670A1 (ru) Являющиеся антагонистами рнк соединения для модуляции экспрессии pik3ca
TN2013000354A1 (en) Synthesis of 2-carboxamide cycloamino urea derivatives
EA201270728A1 (ru) Пуриновые соединения
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof
EA201590656A1 (ru) Азаиндолины

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM